Oleg Mikulinsky
Known title: Chief Information OfficerCIK: 0001544572
Associated companies
Transaction History
| CCEL | ▲ Buy | Option Exercise | 10,000 | $32K | 11/12/2024 | View on chart |
| CCEL | ▲ Buy | Option Exercise | 10,000 | $43K | 11/12/2024 | View on chart |
| CCEL | ▲ Buy | Option Exercise | 20,000 | $64K | 8/25/2022 | View on chart |
| CCEL | ▲ Buy | Option Exercise | 10,000 | $32K | 12/28/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 10, 2026
Cryo-Cell International (CCEL) Q3 Profit Beats Estimates
Cryo-Cell International reported third‑quarter 2026 results showing profit that exceeded analysts’ expectations while revenue remained essentially unchanged. Earnings per share rose to $0.16 from $0.09 a year earlier, and net sales were $7.82 million, a marginal dip from $7.83 million. The stronger earnings come as the stock trades near its 52‑week high and sits just above the 200‑day moving average.
Cryo-Cell International (CCEL) Q3 Profit Beats Estimates. Cryo-Cell International reported third‑quarter 2026 results showing profit that exceeded analysts’ expectations while revenue remained essentially unchanged. Earnings per share rose to $0.16 from $0.09 a year earlier, and net sales were $7.82 million, a marginal dip from $7.83 million. The stronger earnings come as the stock trades near its 52‑week high and sits just above the 200‑day moving average.